Make your money go further for just 25p per day

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · AstraZeneca (AZN)  · GlaxoSmithKline (GSK)  · Tristel (TSTL) 

Coronavirus Pharma and Biotech UK

GSK logo

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes of investors – could really benefit from the period of immense disruption.


But financial results from the UK’s two pharma giants reveal that there is another trend in play here: focus on Covid-19 has dented demand for other, less pressing treatments. Routine GP appointments, prescriptions and subsequently pharma sales have declined in the last three months.

That was reflected in half year results at GlaxoSmithKline (LON: GSK) where an 8% like-for-like decline in sales to £7.6bn came in behind analyst estimates. Falling demand was experienced across all three…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on AstraZeneca

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · Company Insights

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes…


Coronavirus impact: 29 April - surging profits and depression era declines

29/04/2020 · Company Insights

One of the world’s largest companies issued impressive results but the outlook is significantly more challenging.…


More on GlaxoSmithKline

Mega-Trends Portfolio: CRISPR is the future

17/03/2021 · Portfolio

We have covered CRISPR/Cas9 before and hailed it as one of the most important inventions of…


CRISPR: one of the most important inventions of the century?

15/01/2021 · Portfolio

CRISPR is up there with electricity and fire. It stands for clustered regulated interspaced short palindromic…


More on Tristel

Cracking results | Questionable shareholder value

26/02/2024 · Company Insights

News covered here include cracking results from a highly-rated provider of infection prevention products, which has…


Paddling furiously, to go backwards!

23/01/2024 · Company Insights

A popular AIM company covered here is struggling to make a return on substantial revenue –…


More Company Insights

Bonkers Bargain: poised for recovery

16/04/2024 · Gattaca PLC

Takeover mania | Encouraging flows

Bonkers Bargain: update reassures and outlook maintained

11/04/2024

Sign-up to our free email updates

SIGN UP